Glycomacropeptide and Women's Health

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

July 5, 2022

Study Completion Date

July 5, 2022

Conditions
Obesity
Interventions
DIETARY_SUPPLEMENT

glycomacropeptide (GMP)

For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).

Trial Locations (1)

53706

University of Wisconsin-Madison, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT05551091 - Glycomacropeptide and Women's Health | Biotech Hunter | Biotech Hunter